Taurine and vinpocetine combats Parkinson’s disease by boosting dopamine and reducing neuroinflammation in mice: A synergistic approach
Author(s): Onuelu JE, Ebu Iyotor C, Ayovunefe AO, Chidebe EO, Bamitale PE, Demaki EW, Iwhiwhu P, Orovwigho O, Nwabuoku SU, Okunoja M, Okojie DE and Agu CU
Abstract: This study examined A Synergistic approach of co-administering Taurine and Vinpocetine to combat Parkinson's disease, boost Dopamine release, and reduce neuroinflammation in mice was explored in this study. Mice weighing 32-34 g were divided into seven groups (n=9) and given the following treatment for 28 days in a row. Group1: vehicle (10mg/kg p.o); group 2: taurine (20mg/kg p.o); group 3: vinpocetine (20mg/kg p.o); group 4: rotenone (1.5mg/kg i.p; 5% DMSO); group 5: taurine (5mg/kg) +vinpocetine (5mg/kg) p.o; group6: taurine (10mg/kg)+ vinpocetine (10mg/kg) p.o; group 7: Levodopa (LDP)(10mg/kg) p.o in a row for 28 days. Nevertheless, during 14 days, animals from groups 5-7 were also given rotenone (1.5 mg/kg i.p.) alternately. Behavioral task were carried out on day 26-28. The striatum and prefrontal-cortical areas were examined for oxidative stress, neuroinflammatory markers, acetylcholinesterase enzyme activity, dopamine, and alpha synuclein. Rotenone significantly reduced the latency to fall and akinesia-like behavior with numerous slip/error when compared to vehicle groups. When taurine and vinpocetine were co-administered, the latency to fall increased while motor coordination, locomotor deficit, discriminating index, and neuromuscular competence were significantly improved. Additionally, rotenone markedly elevated lipid peroxidation (MDA), while concurrently lowering glutathione (GSH), superoxide dismutase (SOD), and catalase levels in the striatum and prefrontal cortex, respectively. These effects were mitigated by taurine and vinpocetine co-administration. The level of dopamine in the prefrontal cortex and striatum were increased by co-administration of taurine and vinpocetine. Taurine and vinpocetine decrease alpha-synuclein, tumor-necrosis factor ? and interleukin-6 levels in the prefrontal cortex and striatum indicating neuroprotective function. Conclusively, co-administration of taurine and vinpocetine prevent rotenone induced Parkinson disease in mice through augumenting dopamine release by improving the brain’s antioxidant system, inhibiting proinflammatory cytokine release and reducing alpha -synuclein expression in mice’s brain.
DOI: 10.33545/27074447.2025.v7.i2b.114Pages: 134-147 | Views: 68 | Downloads: 39Download Full Article: Click Here
How to cite this article:
Onuelu JE, Ebu Iyotor C, Ayovunefe AO, Chidebe EO, Bamitale PE, Demaki EW, Iwhiwhu P, Orovwigho O, Nwabuoku SU, Okunoja M, Okojie DE, Agu CU.
Taurine and vinpocetine combats Parkinson’s disease by boosting dopamine and reducing neuroinflammation in mice: A synergistic approach. Int J Forensic Med 2025;7(2):134-147. DOI:
10.33545/27074447.2025.v7.i2b.114
